Treatment
Low Dose clinical trials
We’re tracking 457 recruiting studies that include Low Dose, each written for real people, not researchers, below.
Recruiting studies
- NCT05209841Recruiting
Heparin versus saline to keep IV line working
This trial compares using heparin (a blood-thinning medicine) versus saline (salt water) to keep a peripheral IV line open and working. It may help reduce line blockage and improve how well IV treatments can be given.
Sant Pere de Ribes, BarcelonaAges 18–100 - NCT05357794RecruitingPhase 2
Skin-directed radiation plus brentuximab for lymphoma skin disease
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
Houston, TexasAges 18 years+ - NCT05365035RecruitingPhase 2
Phase 2 trial for high-risk blood cancers with timed chemo
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
Houston, TexasAges 18 years+ - NCT05384769Recruiting
Blood test for early lung cancer screening in high-risk people
This study checks whether a blood test (a liquid biopsy) can be used along with standard lung cancer screening to find lung cancer early in people at higher risk. It may help see if the blood test is practical and useful for screening—without needing symptoms.
Duarte, CaliforniaAges 50–80 - NCT05431257RecruitingPhase 2
Azacitidine plus venetoclax for older or unfit AML
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
CopenhagenAges 18 years+ - NCT05446467RecruitingPhase 2
Pembrolizumab before surgery for advanced head and neck cancer
This trial studies whether pembrolizumab, given before surgery, can improve outcomes for certain people with stage III–IVA head and neck squamous cell cancer. It’s typically added alongside low-dose PFAS as part of treatment leading up to standard surgery and afterward medicines/radiation.
Qingdao, ShandongAges 18–85 - NCT05450718RecruitingPhase 4
Low-dose buprenorphine start for opioid use disorder
This trial tests whether starting buprenorphine using a low-dose plan is a safe and workable way to treat opioid use disorder. You may be able to join if you are 18+, have opioid use disorder, and can follow the study medication and visits.
The Bronx, New YorkAges 18 years+ - NCT05462613RecruitingPhase 2/Phase 3
Regorafenib plus aspirin then standard chemo for metastatic bowel cancer
This trial tests whether adding regorafenib and low-dose aspirin before standard chemotherapy can slow metastatic colorectal cancer after it has progressed on prior treatment. It may help by trying a different cancer-fighting approach earlier, followed by the usual chemo plan.
BesançonAges 18 years+ - NCT05476991RecruitingPhase 3
Low-dose colchicine plus ticagrelor to prevent repeat stroke
This Phase 3 study tests whether low-dose colchicine added to ticagrelor (a blood-thinning medicine) helps prevent another ischemic stroke in people whose first stroke was caused by clogged arteries. It aims to lower the risk of repeat stroke after recovery from a recent event.
Paris, ParisAges 18 years+ - NCT05493566RecruitingEarly Phase 1
Low-dose IL-2 plus pembrolizumab for stage IV lung cancer
This early-phase study tests whether low-dose IL-2 combined with pembrolizumab can help treat stage IV non-small cell lung cancer that has not had prior advanced treatment. It may be an option if your tumor has certain immune-marker findings (PD-L1) and you meet safety requirements.
Atlanta, GeorgiaAges 18 years+ - NCT05512351RecruitingPhase 2
Immunotherapy plus low-dose Avastin for recurrent oligodendroglioma
This Phase 2 trial tests an immune treatment (sintilimab, an anti–PD-1 antibody) together with low-dose bevacizumab (Avastin) to treat oligodendroglioma that has come back, including cases detected by tumor DNA in body fluid. It aims to slow or control tumor growth and help reduce symptoms by targeting both the tumor and its blood supply.
Zhengzhou, HenanAges 18 years+ - NCT05557487Recruiting
Real-world low-dose CT screening for people at high lung risk
This study looks at how people at high risk for lung cancer use low-dose CT scans in real life, and what outcomes happen over time. It may help confirm which groups benefit most from regular screening and support safer screening decisions.
Taichung, TaiwanAges 20–80 - NCT05679284Recruiting
Study for retained needle fragments in people who inject drugs
This observational study looks at whether small pieces of drug-injection needles remain in injection sites. You may help by answering a questionnaire and getting X-ray images, which could improve how care and safety are handled for people who inject drugs.
TampereAges 18 years+ - NCT05711615RecruitingPhase 1
Low-dose doxorubicin plus peposertib for advanced sarcoma
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT05724264Recruiting
Lung cancer screening using CT and blood marker tests
This study tests whether combining low-dose chest CT scans with blood “biomarker” tests can help find lung cancer earlier in people at higher risk. You may be asked to have scans and blood tests and then attend follow-up visits over time.
SingaporeAges 50–80 - NCT05733156Recruiting
Low-dose radiation to trigger whole-body cancer effects
This trial tests whether giving a low dose of radiation to one spot can help shrink cancer in other, untreated areas (the “abscopal effect”) in people with multiple metastases. It may help by boosting the body’s response to stereotactic body radiotherapy (focused high-dose radiation) for tumors outside the brain.
SeoulAges 19 years+ - NCT05762731Recruiting
Lung cancer screening for people with family history
This trial offers screening tests to look for lung cancer early in people whose parent, child, or sibling has had lung cancer. It may help find cancer sooner, when treatment is more effective.
Hong Kong, Hong KongAges 50–75 - NCT05772273Recruiting
Test PD-1 drug plus azacitidine and donor cells for AML relapse
This study tests whether combining a PD-1 immune therapy, azacitidine, and low-dose donor lymphocyte infusion (donor immune cells) can treat AML that has come back after a stem cell transplant. It may help some people regain anti-cancer immune activity after relapse.
Suzhou, JiangsuAges Any age - NCT05778591RecruitingPhase 2
Low-dose buprenorphine to improve social drive in schizophrenia
This study tests whether low-dose buprenorphine can improve social motivation in people with schizophrenia. It compares social motivation changes while keeping participants stable on treatment and avoiding certain medicines and substances.
Los Angeles, CaliforniaAges 18–60 - NCT05898594Recruiting
Lung cancer screening for high-risk Black adults
This study is designed to help Black adults at higher risk get lung cancer screening. It checks whether a screening approach can catch lung problems early and connect people to the right next steps.
Chicago, IllinoisAges 50–80 - NCT05929885RecruitingPhase 2
Genotype-guided chemo for metastatic pancreatic cancer
This trial tests a chemo plan that includes different drugs and adjusts the irinotecan dose based on a patient’s genetic test (UGT1A1). It’s designed for people with pancreatic cancer that has spread or cannot be removed with surgery.
SingaporeAges 21–99 - NCT05955313RecruitingPhase 2
Low-dose naltrexone for different types of vulvodynia pain
This Phase 2 study tests whether low-dose naltrexone can reduce pain from vulvodynia. It also looks at how well it works across different vulvodynia types, comparing to what participants are already doing for symptoms.
LublinAges 18–50 - NCT05960721Recruiting
Low-dose blood thinner versus standard care after heart appendage closure
This study looks at whether a lower-dose blood thinner works as well as the usual recommended anti-clot treatment after a procedure that closes off the heart’s left atrial appendage. It may help reduce bleeding risk while still preventing dangerous blood clots.
Xi'an, ShannxiAges 18 years+ - NCT05988710RecruitingPhase 4
Low-dose buprenorphine for pain in opioid-naive adults
This study tests a low-dose form of buprenorphine (a medicine for pain) placed inside the cheek. It is designed for people who have never taken opioids before, to see how well it works for pain and how likely it is to be misused.
Nashville, TennesseeAges 18–65
Common questions
- Are there clinical trials studying Low Dose?
- Yes. Clin2 currently lists 457 recruiting studies that include Low Dose, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Low Dose trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Low Dose an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Low Dose or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.